Heska (NASDAQ:HSKA) Receives “Buy” Rating from Canaccord Genuity

Canaccord Genuity reaffirmed their buy rating on shares of Heska (NASDAQ:HSKA) in a research note released on Monday, May 7th. The brokerage currently has a $95.00 target price on the medical research company’s stock.

Several other equities analysts also recently commented on HSKA. BidaskClub downgraded shares of Heska from a sell rating to a strong sell rating in a research note on Wednesday, January 31st. ValuEngine downgraded shares of Heska from a hold rating to a sell rating in a research note on Friday, February 2nd. Sidoti raised shares of Heska from a neutral rating to a buy rating and set a $94.00 target price for the company in a research note on Monday, February 5th. B. Riley set a $93.00 price target on shares of Heska and gave the company a hold rating in a report on Monday, February 26th. Finally, TheStreet cut shares of Heska from a b- rating to a c+ rating in a report on Friday, March 9th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $100.75.

Shares of Heska opened at $94.43 on Monday, Marketbeat reports. Heska has a 52-week low of $93.67 and a 52-week high of $94.80. The firm has a market capitalization of $692.85 million, a P/E ratio of 53.08 and a beta of 0.68.

Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Friday, May 4th. The medical research company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.12). The business had revenue of $32.77 million for the quarter, compared to analysts’ expectations of $31.65 million. Heska had a net margin of 5.57% and a return on equity of 13.30%. analysts predict that Heska will post 1.93 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its holdings in Heska by 5.5% in the 1st quarter. BlackRock Inc. now owns 928,761 shares of the medical research company’s stock valued at $73,437,000 after acquiring an additional 48,347 shares during the last quarter. Park West Asset Management LLC boosted its stake in shares of Heska by 293.3% during the 4th quarter. Park West Asset Management LLC now owns 347,646 shares of the medical research company’s stock worth $27,885,000 after purchasing an additional 259,256 shares during the period. TimesSquare Capital Management LLC purchased a new position in shares of Heska during the 4th quarter worth about $23,831,000. Bank of New York Mellon Corp boosted its stake in shares of Heska by 110.1% during the 4th quarter. Bank of New York Mellon Corp now owns 210,669 shares of the medical research company’s stock worth $16,897,000 after purchasing an additional 110,391 shares during the period. Finally, Redmile Group LLC purchased a new position in shares of Heska during the 4th quarter worth about $15,753,000. Institutional investors own 84.63% of the company’s stock.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply